Implantable devices formed of non-fouling methacrylate or acrylate polymers

Abstract

Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

1 . An implantable device having a coating comprising a polymer of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 n is a positive integer from 1 to 100,000; 
 R 1  and R 2  are independently C1-C4 alkyl, silyl, siloxy, or phenyl; 
 R 3 , R 4  and R 5  are independently H, C1-C4 alkyl, silyl, siloxy, or phenyl; 
 Z is O or NH; 
 X is absent, O, S, or NR 6 ; and 
 R 6  is H, C1-C4 alkyl, or phenyl. 
 
     
     
         2 . The implantable device of  claim 1 , wherein:
 R 3 , R 4 , R 5 , and R 6  are independently CH 3 , ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl; and   Z is O.   
     
     
         3 . The implantable device of  claim 1 , wherein:
 Z is O; and   X is O or NH.   
     
     
         4 . The implantable device of  claim 1 , wherein the polymer is poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2-methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2-ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(2-ethoxyethyl methacrylate) (PEEM), or a combination thereof. 
     
     
         5 . The implantable device of  claim 1 , further comprising a biocompatible polymer, blended or bonded with the polymer of Formula I. 
     
     
         6 . The implantable device of  claim 1 , further comprising a bioactive agent. 
     
     
         7 . The implantable device of  claim 6 , wherein the bioactive agent is paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxyl)propyl-rapamycin, 40-O-[2-(2-hydroxyl)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, ABT-578, clobetasol, or a combination thereof. 
     
     
         8 . The implantable device of  claim 1  which is a stent. 
     
     
         9 . The implantable device of  claim 7 , which is a stent. 
     
     
         10 . An absorbable device formed of a material comprising a polymer of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 n is a positive integer from 1 to 100,000; 
 R 1  and R 2  are independently C1-C4 alkyl, silyl, siloxy, or phenyl; 
 R 3 , R 4  and R 5  are independently H, C1-C4 alkyl, silyl, siloxy, or phenyl; 
 Z is O or NH; 
 X is absent, O, S, or NR 6 ; and 
 R 6  is H, C1-C4 alkyl, or phenyl. 
 
     
     
         11 . The absorbable device of  claim 10 , wherein:
 R 3 , R 4 , R 5 , and R 6  are independently CH 3 , ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl; and   Z is O.   
     
     
         12 . The absorbable device of  claim 10 , wherein:
 Z is O; and   X is O or NH.   
     
     
         13 . The absorbable device of  claim 10 , wherein the polymer is poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2-methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2-ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(2-ethoxyethyl methacrylate) (PEEM), or a combination thereof. 
     
     
         14 . The absorbable device of  claim 10 , further comprising a bioactive agent. 
     
     
         15 . The implantable device of  claim 14 , wherein the bioactive agent is paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxyl)ethyl-rapamycin (everolimus), 40-O-(3-hydroxyl)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, ABT-578, clobetasol, or a combination thereof. 
     
     
         16 . The implantable device of  claim 10  which is a stent. 
     
     
         17 . A method of treating a disorder in a patient comprising implanting in the patient the implantable device of  claim 9 , wherein the disorder is atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or a combination thereof. 
     
     
         18 . A method of treating a disorder in a patient comprising implanting in the patient the implantable device of  claim 16 , wherein the disorder is atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or a combination thereof.